Targeting keratinocyte DC-SIGN with heparin analogue octaparin restores barrier and immune homeostasis in atopic dermatitis
International Immunopharmacology · 2026-07 · 180 · 116723
DOI: 10.1016/j.intimp.2026.116723 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-07. Verfasst von Qiaozhen Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China; Key Laboratory of Metabolic Engineering and Biosy…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Cell Adhesion Molecules, Keratinocytes, Lectins, C-Type. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by dysregulated immune responses and impaired epidermal barrier function. A major therapeutic challenge is the identification of molecular targets capable of coordinately regulating both processes. Here, we identify dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) on keratinocytes as one such target. We demonstrate functional expression of DC-SIGN on keratinocytes and show that its engagement by a synthetic heparin analogue-exemplified by the oligosaccharide octaparin-produces profound therapeutic benefits. In a DNCB-induced murine model of AD, topical application of octaparin alleviated disease severity, suppressed both Th1- and Th2-type inflammatory responses, and restored expression of key epidermal barrier proteins such as filaggrin and loricrin. Metabolomic profiling further confirmed that octaparin treatment globally reversed disease-associated metabolic perturbations. Mechanistically, engagement of DC-SIGN on keratinocytes attenuated JAK-STAT signalling induced by key AD-associated cytokines, including IFN-γ and IL-4/IL-13. This attenuation led to reduced production of pro-inflammatory chemokines and cytokines, accompanied by increased expression of barrier-related genes. Critically, inhibition of DC-SIGN abolished the therapeutic effects of octaparin, establishing a causal requirement for this receptor. Our findings unveil a previously unrecognized role for keratinocyte DC-SIGN in coordinating immune and barrier responses and highlight it as a druggable target for novel therapeutic strategies in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China; Key Laboratory of Metabolic Engineering and Biosynthesis Technology, Ministry of Industry and Information Technology, 2…
Förderung
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Liu, Q., Chen, S., Lin, W., Yu, N., Fang, R., Wang, J., Zhang, J., & Xu, X. (2026). Targeting keratinocyte DC-SIGN with heparin analogue octaparin restores barrier and immune homeostasis in atopic dermatitis. International Immunopharmacology, 180, 116723. https://doi.org/10.1016/j.intimp.2026.116723
Vancouver
Liu Q, Chen S, Lin W, Yu N, Fang R, Wang J, et al. Targeting keratinocyte DC-SIGN with heparin analogue octaparin restores barrier and immune homeostasis in atopic dermatitis. International Immunopharmacology. 2026;180:116723. doi:10.1016/j.intimp.2026.116723
BibTeX
@article{Liu2026,
author = {Liu, Qiaozhen and Chen, Simeng and Lin, Wenyu and Yu, Ning and Fang, Rui and Wang, Jinglong and Zhang, Jianfa and Xu, Xi},
title = {Targeting keratinocyte DC-SIGN with heparin analogue octaparin restores barrier and immune homeostasis in atopic dermatitis},
journal = {International Immunopharmacology},
year = {2026},
volume = {180},
pages = {116723},
doi = {10.1016/j.intimp.2026.116723}
}
EUVIMED